Sernova and Seraxis close US$11.2M financing for diabetes trial
Seraxis notes are expected to convert into BetaNova stock if the merger closes; the first SR-02 patient dose is targeted for Q1 2027.
Adrian Kessler
A US$11.2 million financing brings a planned type 1 diabetes cell-therapy trial closer, as Sernova Biotherapeutics Inc. TSESVA OTCMKTSSEOVF said Monday that Seraxis Holdings, Inc. had closed the round ahead of their proposed BetaNova merger. The amount exceeds the US$10 million target and is intended to support manufacturing and the first SR-02 patient dose targeted for the first quarter of 2027.
Seraxis issued convertible notes and common stock purchase warrants on a non-brokered basis. The notes are expected to convert into BetaNova common stock if the merger closes, but the Oct. 5 release gives no conversion price, warrant strike or separate date for the financing close.
Toronto-based Sernova is a clinical-stage regenerative-medicine developer whose Cell Pouch implant is designed to host pancreatic cells for people with type 1 diabetes.
At 9:30 a.m. EDT on Oct. 5, Sernova shares stood at C$0.11 on the Toronto Stock Exchange, according to TSESVA. The quote showed an unchanged opening price from the Oct. 2 close.
Financing Backs Manufacturing And Enrollment
The Oct. 5 announcement allocates proceeds to cGMP manufacturing of SR-02, Seraxis's stem-cell-derived pancreatic islet cells. It also sets fourth-quarter 2026 enrollment for a Phase 1/2 study and targets first dosing in the first quarter of 2027. Initial clinical data are anticipated in the first half of 2027 under what the company describes as an FDA-cleared investigational new drug application.
“Closing the financing provides the resources to advance the manufacturing activities required to support SR-02 islet cells and prepare for initiation of the Phase 1/2 clinical trial,” Seraxis president and chief executive Will Rust said in the Oct. 5 release.
A cleared investigational application permits the clinical study to proceed; it is not evidence that the cell therapy works. The release does not give a patient count, a trial endpoint or an SR-02 safety result, because it reports a financing and planned trial rather than a readout.
Read more: Surrozen gains FDA IND clearance for SZN-8141 macular edema trial
Management at both companies took part in the financing alongside existing holders and new investors, although the release does not identify a lead investor. It also does not give a combined cash balance, spending rate or cash runway. Without those figures, the US$11.2 million cannot be translated into a sourced estimate of how long BetaNova could fund operations.
Proceeds are also expected to advance SR-03, a gene-edited follow-on islet program, toward an investigational new drug submission in the second half of 2027. That is a separate program from SR-02, whose first patient dosing is planned much sooner.
Read more: Alvotech gains FDA approval for second SIMLANDI production suite
The Merger Remains Subject To Approvals
Sernova and Seraxis signed their definitive merger agreement on Sept. 7, according to the Oct. 5 release. The combined company would bring Seraxis's islet-cell programs and cGMP manufacturing capabilities together with Sernova's Cell Pouch, subject to required approvals and customary closing conditions. Each company's shareholders are expected to own approximately half of BetaNova on an undiluted basis; the release does not set a firm merger closing date.
Vertex Pharmaceuticals Incorporated NASDAQVRTX described its own stem-cell-derived islet therapies for type 1 diabetes in its May 4 results. The overlap is cell replacement, while Sernova and Seraxis still need to dose SR-02 patients and report the first results. At 4 p.m. EDT on Oct. 2, the iShares Biotechnology ETF stood at US$205.29 on Nasdaq, according to NASDAQIBB. That was the last trading day before the financing announcement.
BetaNova targets readiness for a Nasdaq listing in the first quarter of 2027, subject to exchange requirements and approvals. Patient enrollment planned for the fourth quarter of 2026 is the next dated operating milestone; it will show whether the group is prepared for the first SR-02 dose targeted for the first quarter of 2027.
